Published in Drug Law Weekly, August 7th, 2007
Barr filed its ANDA containing a paragraph IV certification for a generic TEMODAR product with the U.S. Food & Drug Administration (FDA) in March 2007, and received notification of the application's acceptance for filing in June 2007. Following receipt of the notice from the FDA, Barr notified...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.